Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors
Vaso (OTCQX: VASO) announced key executive leadership changes effective January 1, 2025. Jane Moen, who has served as a Director since 2020, was appointed Chief Operating Officer while retaining her role as President of VasoHealthcare. Jonathan Newton was promoted to Chief Financial Officer from Co-Chief Financial Officer, with Michael Beecher transitioning to a financial and investor relations advisory role.
Additionally, Edgar Rios, who has served as an independent Director since 2011, was elected Vice Chairman of the Board of Directors and will continue as Chairman of the Board's Audit Committee. The company also appointed Kimberly Decker of Barley Snyder LLP as new corporate and securities outside counsel.
CEO Dr. Jun Ma emphasized these changes align with Vaso's human capital mission and 2025 strategy, focusing on organic growth across their diversified portfolio in human capital, MedTech, and information technology businesses.
Vaso (OTCQX: VASO) ha annunciato importanti cambiamenti nella leadership esecutiva con effetto dal 1° gennaio 2025. Jane Moen, che ricopre il ruolo di Direttore dal 2020, è stata nominata Chief Operating Officer mantenendo anche il suo ruolo di Presidente di VasoHealthcare. Jonathan Newton è stato promosso a Chief Financial Officer da Co-Chief Financial Officer, mentre Michael Beecher passerà a un ruolo di consulenza finanziaria e relazioni con gli investitori.
Inoltre, Edgar Rios, che è stato Direttore indipendente dal 2011, è stato eletto Vice Presidente del Consiglio di Amministrazione e continuerà come Presidente del Comitato di Audit del Consiglio. L'azienda ha anche nominato Kimberly Decker dello studio legale Barley Snyder LLP come nuovo consulente esterno in materia societaria e di titoli.
Il CEO Dr. Jun Ma ha sottolineato che questi cambiamenti sono in linea con la missione sul capitale umano di Vaso e la strategia per il 2025, focalizzandosi sulla crescita organica attraverso il loro portafoglio diversificato nei settori del capitale umano, MedTech e tecnologie dell'informazione.
Vaso (OTCQX: VASO) anunció cambios clave en su liderazgo ejecutivo con efecto a partir del 1 de enero de 2025. Jane Moen, quien se ha desempeñado como Directora desde 2020, fue nombrada COO mientras mantiene su cargo como Presidenta de VasoHealthcare. Jonathan Newton fue ascendido a CFO desde Co-CFO, y Michael Beecher pasará a un rol de asesoría financiera y de relaciones con inversores.
Además, Edgar Rios, quien ha sido Director independiente desde 2011, ha sido elegido Vicepresidente de la Junta Directiva y continuará como Presidente del Comité de Auditoría de la Junta. La empresa también nombró a Kimberly Decker de Barley Snyder LLP como nueva asesora externa en materia corporativa y de valores.
El CEO Dr. Jun Ma enfatizó que estos cambios están alineados con la misión de capital humano de Vaso y la estrategia para 2025, enfocándose en el crecimiento orgánico a través de su cartera diversificada en capital humano, MedTech y negocios de tecnología de la información.
Vaso (OTCQX: VASO)는 2025년 1월 1일부터 발효되는 주요 경영진 변화를 발표했습니다. Jane Moen은 2020년부터 이사로 재직 중이며, COO로 임명되었고 VasoHealthcare의 사장직도 함께 유지합니다. Jonathan Newton은 공동 CFO에서 CFO로 승진했으며, Michael Beecher는 재무 및 투자자 관계 자문 역할로 전환합니다.
추가로, Edgar Rios는 2011년부터 독립 이사로 재직 중이며 이사회 부의장으로 선출되었고 감사위원회 의장직을 계속 맡습니다. 또한, 회사는 Barley Snyder LLP의 Kimberly Decker를 새로운 외부 기업 및 증권 자문으로 임명했습니다.
CEO Dr. Jun Ma는 이러한 변화가 Vaso의 인적 자본 미션과 2025 전략에 부합하며 인적 자본, MedTech, 정보기술 비즈니스에서의 유기적 성장을 중시하고 있음을 강조했습니다.
Vaso (OTCQX: VASO) a annoncé d'importants changements dans sa direction exécutive, qui entreront en vigueur le 1er janvier 2025. Jane Moen, qui est directrice depuis 2020, a été nommée directrice des opérations tout en conservant son poste de présidente de VasoHealthcare. Jonathan Newton a été promu directeur financier, passant de co-directeur financier, tandis que Michael Beecher se dirigera vers un rôle de conseiller en finances et en relations avec les investisseurs.
De plus, Edgar Rios, qui est administrateur indépendant depuis 2011, a été élu vice-président du conseil d'administration et continuera en tant que président du comité d'audit du conseil. L'entreprise a également nommé Kimberly Decker du cabinet Barley Snyder LLP comme nouvelle conseillère externe en affaires corporatives et en valeurs mobilières.
Le PDG Dr. Jun Ma a souligné que ces changements s'alignent avec la mission de capital humain de Vaso et la stratégie 2025, en mettant l'accent sur la croissance organique à travers leur portefeuille diversifié dans les secteurs du capital humain, MedTech et des technologies de l'information.
Vaso (OTCQX: VASO) hat wichtige Veränderungen in der Führungsebene mit Wirkung zum 1. Januar 2025 bekannt gegeben. Jane Moen, die seit 2020 als Direktorin tätig ist, wurde zur Chief Operating Officer ernannt, während sie auch ihre Position als Präsidentin von VasoHealthcare beibehält. Jonathan Newton wurde vom Co-Chief Financial Officer zum Chief Financial Officer befördert, während Michael Beecher in eine beratende Rolle im Bereich Finanzen und Anlegerbeziehungen wechselt.
Darüber hinaus wurde Edgar Rios, der seit 2011 als unabhängiger Direktor tätig ist, zum stellvertretenden Vorsitzenden des Aufsichtsrats gewählt und wird weiterhin den Vorsitz des Prüfungsausschusses des Aufsichtsrats übernehmen. Das Unternehmen hat auch Kimberly Decker von Barley Snyder LLP als neue externe Beraterin für Unternehmens- und Wertpapieranliegen ernannt.
CEO Dr. Jun Ma betonte, dass diese Änderungen im Einklang mit Vaso's Zielsetzung im Bereich Human Capital und der Strategie 2025 stehen, die sich auf organisches Wachstum in ihrem diversifizierten Portfolio in den Bereichen Human Capital, MedTech und Informationstechnologie konzentriert.
- Strategic leadership restructuring with internal promotions indicating succession planning
- Retention of experienced board member Edgar Rios (since 2011) as Vice Chairman
- Continuity in leadership with Jane Moen maintaining dual roles
- None.
PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments to the Vaso management team and Board of Directors, effective January 1, 2025.
- Jane Moen was appointed Vaso Corporation’s Chief Operating Officer. She will continue in her role as President of VasoHealthcare, a Vaso Corporation subsidiary. Ms. Moen has served as a Director of Vaso Corporation’s Board since 2020.
- Jonathan Newton was promoted to Chief Financial Officer of Vaso Corporation from his previous role as Vaso’s Co-Chief Financial Officer. As part of this development, Michael Beecher, previously Co-Chief Financial Officer, will transition to a Vaso financial and investor relations advisory role.
- Edgar Rios was elected Vice Chairman of Vaso Corporation’s Board of Directors. Mr. Rios has served as an independent Director of Vaso since 2011. He will also continue in his role as Chairman of the Board’s Audit Committee.
Furthermore, Vaso Corporation named new corporate and securities outside counsel, Kimberly Decker of the law firm Barley Snyder LLP.
Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation commented, “Today’s executive changes and board appointments reflect Vaso Corporation’s commitment to its human capital mission and our focus on advancing our dedicated leaders. As we implement our 2025 strategy during this pivotal time in our corporate history, we are optimistic on our path and our competitive position as a leading human capital, MedTech, and information technology business. As we have recently articulated, our top priority in 2025 will be to continue growing organically across our diversified portfolio businesses, working closely with our customers and partners, while continuing to explore new strategic opportunities. We cannot be prouder of having leaders such as Jane and Jonathan in their expanded executive roles. Their devotion to Vaso has contributed to our success and I am looking forward to continuing to work with them and our entire leadership team.”
“We are also delighted to name Kimberly Decker from the prestigious law firm Barley Snyder LLP to work with us as legal counsel on corporate and securities matters. Lastly, the election of Edgar Rios, a respected and trusted Board Member, as Vaso’s new Vice Chairman is a natural progression and on behalf of the entire Board, I would like to thank him for his continued service to the Vaso mission,” Dr. Ma added.
About Vaso Corporation
Headquartered in Plainview New York, Vaso Corporation is a leading human capital, information technology and MedTech business with a focus on healthcare professional sales services, network and IT services across sectors, and proprietary medical products. Vaso Corporation is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GE HealthCare's diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.
For additional information, please visit www.vasocorporation.com or contact us at
info@vasocorporation.com
Investor Contacts:
Michael J. Beecher
Investor Relations
Phone: 516-508-5840 Email: mbeecher@vasocorporation.com
V&S Strategic Consulting ir@vasocorporation.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
# # #
FAQ
Who are the new executive appointments at Vaso (VASO) announced in January 2025?
What changes were made to Vaso 's (VASO) CFO position in 2025?
What is Vaso 's (VASO) strategic focus for 2025?
Who was appointed as Vaso 's (VASO) new legal counsel in 2025?
